drugset / Trial / NCT03509883

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

NCT03509883

Phase 1 Completed 94 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose of apixaban twice during the course of the study.

Timeline

Start
2018-04-26
Primary completion
2018-06-15
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral

Indications

No indication recorded.